Carpal Tunnel & Entrapment Neuropathies

📋 Key Information Summary

📋

Carpal tunnel syndrome (CTS) is the most common entrapment neuropathy in Australia, affecting 3–6% of the adult population with higher prevalence in women and certain occupational groups.
Typical CTS presents with nocturnal paraesthesiae in the median nerve distribution (thumb, index, middle, lateral ring finger), often waking the patient from sleep.
Phalen's test (wrist flexion 60 s) and Tinel's sign (percussion over carpal tunnel) are useful bedside provocative tests but have moderate sensitivity and specificity — clinical diagnosis remains paramount.
First-line management is night-time wrist splinting in neutral position for ≥6 weeks; this alone resolves symptoms in many mild-to-moderate cases.
Corticosteroid injection (methylprednisolone 40 mg or triamcinolone 20 mg locally) provides short-to-medium-term relief and is PBS-listed; can be repeated once if initial response is good but relapses.
Nerve conduction studies (NCS) are indicated when the diagnosis is uncertain, symptoms are severe or persistent despite conservative therapy, or surgical decompression is being considered (Medicare rebate Item 11000 series).
Carpal tunnel release (open or endoscopic) is indicated for severe or refractory CTS with thenar wasting, constant numbness, or failed ≥3 months of conservative management.
Cubital tunnel syndrome (ulnar nerve at elbow) presents with medial forearm/hand numbness and grip weakness; conservative measures include avoiding elbow flexion and padding; surgery indicated for motor deficit or refractory cases.
Meralgia paraesthetica (lateral femoral cutaneous nerve) causes lateral thigh burning/numbness; usually managed conservatively with weight reduction, looser clothing, and gabapentinoids; surgery rarely required.
Radial tunnel syndrome causes deep proximal forearm pain worsened by forearm supination against resistance; distinguish from lateral epicondylitis; usually responds to physiotherapy and activity modification.
Diabetes mellitus, hypothyroidism, obesity, pregnancy, and rheumatoid arthritis are important systemic risk factors for entrapment neuropathies — screen accordingly.
Aboriginal and Torres Strait Islander peoples may have higher rates of undiagnosed diabetes and obesity, increasing entrapment neuropathy risk; culturally appropriate screening and access to specialist services in remote areas remain critical gaps.

Introduction & Australian Epidemiology

Entrapment neuropathies result from focal compression or tension on a peripheral nerve at an anatomical bottleneck, leading to ischaemia, demyelination, and — if prolonged — axonal degeneration. Carpal tunnel syndrome (CTS) is by far the most common, but cubital tunnel syndrome, radial tunnel syndrome, and meralgia paraesthetica are also frequently encountered in Australian primary care and specialist practice.

In Australia, CTS has an estimated prevalence of 3–6% in the general adult population and accounts for the majority of upper-limb nerve conduction studies performed. The Australian Institute of Health and Welfare (AIHW) data indicate that carpal tunnel release is among the most commonly performed hand and wrist procedures in both public and private hospitals, with over 20,000 procedures nationally per year. Women are affected approximately three times more often than men, and peak incidence occurs between ages 45 and 64.

Occupational factors remain debated in the Australian literature. While repetitive manual work, vibration exposure, and sustained wrist flexion/extension are associated with CTS in Workers' Compensation claims (Safe Work Australia), population-based studies suggest that the attributable occupational risk is smaller than previously believed, with systemic metabolic factors (diabetes, obesity, thyroid disease, pregnancy) playing an equally important role.

📊

Australian burden: Carpal tunnel release costs the Australian health system approximately $80–120 million annually. Early conservative management can significantly reduce surgical referral rates and associated costs.

Carpal Tunnel Syndrome

Typical Symptoms

CTS classically presents with intermittent or constant paraesthesiae (tingling, burning, numbness) in the distribution of the median nerve distal to the carpal tunnel — affecting the thumb, index finger, middle finger, and the radial half of the ring finger. The little finger is characteristically spared.

Nocturnal symptoms are the hallmark — patients report waking with a "dead" or tingling hand, often relieved by shaking or hanging the hand over the side of the bed.
Activity-related symptoms — gripping, driving, holding a phone, or repetitive wrist flexion may provoke paraesthesiae.
Weakness and clumsiness — dropping objects, difficulty with jars and buttons suggests thenar muscle involvement (abductor pollicis brevis) and indicates more advanced disease.
Pain may radiate proximally into the forearm, wrist, or even the shoulder, but isolated proximal arm pain without digital paraesthesiae is atypical for CTS.
Constant numbness in the median nerve territory with two-point discrimination >6 mm at the index finger pulp suggests severe axonal loss and warrants urgent surgical consideration.

Provocative Clinical Tests

Test	Technique	Positive Result	Sensitivity / Specificity
Phalen's test	Patient holds wrists in full flexion (palms together) for 60 seconds	Reproduction of median nerve paraesthesiae within 60 s	Sens 68–83% / Spec 40–73%
Reverse Phalen (prayer sign)	Wrist extension (dorsiflexed prayer position) for 60 s	Paraesthesiae in median distribution	Sens 48–67% / Spec 56–75%
Tinel's sign	Percussion over the carpal tunnel (volar wrist crease)	Electric shock or tingling into median nerve fingers	Sens 38–67% / Spec 60–83%
Carpal tunnel compression test	Direct sustained pressure over carpal tunnel with thumbs for 30 s	Reproduction of symptoms	Sens 64–87% / Spec 50–73%
Thenar wasting	Visual inspection and palpation of the thenar eminence	Visible or palpable atrophy of abductor pollicis brevis	Low sensitivity but highly specific for severe CTS

⚠️

Clinical pearl: No single provocative test is definitive. A combination of positive Phalen's or Tinel's with a classic symptom history has the best diagnostic accuracy. Bilateral symptoms are common (50–70%) and do not exclude CTS. Always examine for thenar wasting and assess abductor pollicis brevis strength.

Initial Conservative Management — Wrist Splinting

Night-time wrist splinting in neutral position (0° extension) is the recommended first-line therapy for mild-to-moderate CTS. A rigid or semi-rigid splint that maintains the wrist in neutral prevents flexion during sleep, reducing intraneural pressure.

Duration: Minimum 6 weeks; often 8–12 weeks to assess full benefit.
Wear schedule: Nightly; some patients benefit from daytime wear during aggravating activities.
Availability: Prefabricated wrist splints (e.g., Futuro®, Mueller®) are available over the counter at pharmacies for approximately $20–40; custom thermoplastic splints from a hand therapist (Item 10950 MBS) may be preferred for complex cases.
Evidence: A Cochrane review (2012) and subsequent RCTs show that splinting significantly improves symptoms at 6 weeks compared to no treatment, with NNT ≈ 4.
Adjuncts: Nerve gliding exercises (median nerve neurodynamic mobilisation) may provide additional benefit when supervised by a physiotherapist or hand therapist.

Corticosteroid Injection

Local corticosteroid injection into the carpal tunnel is recommended when splinting alone provides insufficient relief after 4–6 weeks, or when rapid symptom control is needed while awaiting specialist review or surgery.

💊

Methylprednisolone acetate

Depo-Medrol® · Corticosteroid injection

Adult dose 40 mg (1 mL) injected into carpal tunnel, single dose

Route Local injection (ultrasound guidance recommended)

Frequency Single injection; may repeat once after 8–12 weeks if good initial response followed by relapse

Duration Symptom relief typically 4–12 weeks; effect wanes over months

Renal adjustment None required (local injection)

PBS status ✔ PBS General Benefit

💊

Triamcinolone acetonide

Kenacort®-A 10 / Kenalog® 40 · Corticosteroid injection

Adult dose 10–20 mg (0.25–0.5 mL of 40 mg/mL preparation) into carpal tunnel

Route Local injection (ultrasound guidance recommended)

Frequency Single injection; may repeat once after 8–12 weeks

Renal adjustment None required (local injection)

PBS status ✔ PBS General Benefit

⚠️

Injection technique: Ultrasound-guided carpal tunnel injection improves accuracy and reduces the risk of intraneural injection. If ultrasound is not available, the landmark-based approach (inject at the proximal wrist crease, ulnar to palmaris longus tendon, directed distally at 30–45°) remains acceptable in experienced hands. Aspirate before injecting to exclude intravascular placement. Avoid injecting directly into the median nerve.

When to Request Nerve Conduction Studies

Nerve conduction studies (NCS) and electromyography (EMG) are not required to diagnose classic CTS with a clear clinical history. However, NCS/EMG are indicated in the following circumstances:

Diagnostic uncertainty — atypical symptoms, symptoms in non-median distribution, or suspected alternative diagnoses (cervical radiculopathy, polyneuropathy, brachial plexopathy).
Severe or progressive symptoms — constant numbness, thenar wasting, or weakness to help grade severity and guide urgency of surgical referral.
Failed conservative management — prior to surgical decompression to confirm the diagnosis and exclude co-existing proximal pathology.
Medicolegal or Workers' Compensation cases where objective documentation is required.
Recurrent symptoms after surgery — to assess for incomplete release, fibrosis, or misdiagnosis.

Australian access and MBS: NCS/EMG is available in most metropolitan centres and many regional hospitals. The MBS Item 11000 series provides a Medicare rebate for nerve conduction studies when requested by a specialist (neurologist, rehabilitation physician, or surgeon). Some GPs can access NCS through community neurophysiology services, though specialist interpretation is recommended. Wait times in the public system can be 4–12 weeks; private access is typically within 1–2 weeks.

Other Entrapment Neuropathies

Cubital Tunnel Syndrome (Ulnar Nerve at the Elbow)

Cubital tunnel syndrome is the second most common upper-limb entrapment neuropathy. The ulnar nerve is compressed at the elbow, most commonly at the cubital tunnel (behind the medial epicondyle) or the Osborne's ligament (arcuate ligament).

Symptoms and Signs

Paraesthesiae and numbness in the ulnar 1½ fingers (ring and little finger) and ulnar border of the hand.
Medial elbow pain, often worse with sustained elbow flexion (e.g., holding a phone, sleeping with arms bent).
Grip weakness and clumsiness — difficulty opening jars, turning keys.
Severe/signs of denervation: Intrinsic hand muscle wasting (first dorsal interosseous, hypothenar muscles), clawing of ring and little fingers (ulnar claw hand), Wartenberg's sign (abducted little finger), Froment's sign (IP flexion of thumb on pinch grip).

Bedside Tests

Tinel's at the elbow — percussion over the ulnar nerve in the cubital tunnel.
Elbow flexion test — full elbow flexion with wrist extension for 60 s; reproduction of ulnar symptoms.
Froment's sign — compensatory thumb IP flexion when pinching paper, indicating adductor pollicis weakness.

Conservative vs Surgical Management

Mild

Intermittent Paraesthesiae Only

No motor deficit, no muscle wasting, intermittent symptoms mainly with elbow flexion

Setting: GP management — activity modification, elbow splinting at night in 45° flexion, avoid prolonged elbow flexion, padding for leaning. Review in 8–12 weeks.

Moderate

Persistent Symptoms ± Mild Weakness

Constant paraesthesiae, mild grip weakness, no overt wasting

Setting: GP-initiated conservative therapy + neurology/orthopaedic referral for NCS. Gabapentinoids for neuropathic pain. Consider corticosteroid injection around (not into) the nerve if inflammatory aetiology suspected.

Severe

Motor Deficit and/or Muscle Wasting

Intrinsic hand wasting, claw deformity, constant numbness, significant weakness

Setting: Urgent surgical referral — ulnar nerve decompression ± transposition. Delay risks irreversible motor loss. NCS to confirm and grade severity.

Radial Tunnel Syndrome

Radial tunnel syndrome involves compression of the posterior interosseous nerve (deep branch of the radial nerve) as it passes through the radial tunnel — from the radiocapitellar joint through the supinator muscle (Arcade of Frohse). It is often misdiagnosed as lateral epicondylitis.

Key Distinguishing Features from Lateral Epicondylitis

Feature	Radial Tunnel Syndrome	Lateral Epicondylitis
Pain location	Deep, aching pain 3–5 cm distal to lateral epicondyle (over the radial tunnel)	Lateral epicondyle itself
Aggravating factor	Forearm supination against resistance; resisted middle finger extension	Wrist extension against resistance
Tenderness	Tenderness over the radial tunnel (distal to epicondyle)	Tenderness at the lateral epicondyle
Paraesthesiae	Usually absent (pure motor/sensory deep branch)	Absent
Weakness	Late — finger drop if posterior interosseous nerve palsy develops	Weakness secondary to pain

Management

Conservative (first-line): Activity modification (avoid repetitive supination/pronation), physiotherapy focusing on forearm extensor stretching and strengthening, counterforce bracing, NSAIDs for 2–4 weeks.
Corticosteroid injection: May be trialled at the radial tunnel (deep to the extensor carpi radialis brevis); evidence is limited and effect size is small.
Referral for surgery: Indicated for refractory cases failing 3–6 months of conservative therapy, or if posterior interosseous nerve palsy develops (finger/wrist drop). Surgical decompression of the radial tunnel has variable outcomes (60–80% improvement).

Meralgia Paraesthetica (Lateral Femoral Cutaneous Nerve)

Meralgia paraesthetica results from compression of the lateral femoral cutaneous nerve (LFCN) as it passes beneath or through the inguinal ligament, typically near the anterior superior iliac spine (ASIS). It is a purely sensory nerve; motor involvement does not occur.

Symptoms

Burning, tingling, or numbness over the anterolateral thigh — from the ASIS to the mid-thigh.
Symptoms are worsened by standing, walking, or hip extension and relieved by sitting or hip flexion.
Allodynia (pain from light touch to the affected area) may be present in chronic cases.

Risk Factors

Obesity (BMI >30) — the single strongest modifiable risk factor.
Tight clothing — belts, corsets, tight waistbands, tool belts.
Pregnancy — increased abdominal girth and intra-abdominal pressure.
Diabetes mellitus — predisposes to nerve vulnerability.
Post-surgical — iliac bone graft harvest, hip replacement (direct nerve injury).

Conservative vs Referral

First-line

Conservative Management

Weight loss (if overweight), looser clothing, avoid prolonged standing, activity modification. 80–90% of cases resolve or improve significantly.

Setting: GP management with 6–12 week review

Second-line

Pharmacotherapy

Gabapentin 300–600 mg TDS or pregabalin 75–150 mg BD for neuropathic pain. Amitriptyline 10–25 mg nocte may be used. Local nerve block (lignocaine ± corticosteroid at ASIS) can provide diagnostic confirmation and therapeutic relief.

Setting: GP initiation, specialist referral if insufficient response

Refractory

Surgical Decompression or Neurectomy

Reserved for persistent, disabling symptoms refractory to ≥6 months of conservative and pharmacological management. Surgical decompression (release of the inguinal ligament) or neurectomy (division of the nerve) — neurectomy provides more reliable pain relief but causes a permanent area of numbness.

Setting: Specialist surgical referral (vascular or general surgeon)

💊

Gabapentin

Neurontin® · Generic available · Anticonvulsant/neuropathic pain

Adult dose Start 300 mg OD, titrate to 300 mg TDS; max 1800 mg/day in divided doses

Paediatric dose ≥12 years: as per adult. <12 years: specialist guidance only

Renal adjustment eGFR 30–59: max 600 mg/day; eGFR 15–29: max 300 mg/day; eGFR <15: 300 mg alternate days; dialysis: 200–300 mg post-dialysis

Key side effects Drowsiness, dizziness, peripheral oedema, weight gain

PBS status ✔ PBS General Benefit (Authority Required for neuropathic pain indication)

💊

Pregabalin

Lyrica® · Generic available · Anticonvulsant/neuropathic pain

Adult dose Start 75 mg BD; titrate to 150 mg BD; max 300 mg BD

Paediatric dose Not recommended <18 years for neuropathic pain

Renal adjustment eGFR 30–59: max 150 mg BD; eGFR 15–29: 75 mg OD–BD; eGFR <15: 25–75 mg OD

Key side effects Drowsiness, dizziness, weight gain, peripheral oedema, blurred vision

PBS status ⚠ PBS Authority Required — neuropathic pain refractory to other agents

Pathophysiology

Entrapment neuropathies share a common pathophysiological mechanism: focal nerve compression at an anatomical site where the nerve passes through a rigid or semi-rigid tunnel or beneath a fibrous band.

Mechanical compression reduces intraneural blood flow, causing endoneurial oedema and ischaemia. Venous congestion occurs first, followed by arterial insufficiency if compression persists.
Demyelination at the compression site produces conduction block and/or slowing, detectable on NCS as prolongation of distal motor latency or reduction in sensory nerve action potential amplitude.
In chronic compression, segmental demyelination progresses to secondary axonal degeneration, which is associated with muscle denervation (visible on EMG as fibrillation potentials and positive sharp waves) and poorer prognosis for full recovery after decompression.
In CTS specifically: The carpal tunnel is an osseofibrous space bounded by the carpal bones dorsally and the flexor retinaculum (transverse carpal ligament) volarly. Increased pressure within the tunnel (from synovial hypertrophy, oedema, space-occupying lesions, or anatomical variation) compresses the median nerve. Normal carpal tunnel pressure is 2–10 mmHg; in CTS, it may exceed 30 mmHg at rest and rise further with wrist flexion.
Systemic predisposing conditions: Diabetes mellitus causes endoneurial microangiopathy making nerves more vulnerable to compression. Hypothyroidism causes mucopolysaccharide deposition in the flexor tenosynovium. Rheumatoid arthritis causes synovial hypertrophy. Obesity increases carpal tunnel pressure.

Investigations

Nerve Conduction Studies and Electromyography (NCS/EMG)

Essential

Nerve conduction studies (NCS)

Gold standard electrophysiological test for entrapment neuropathies. Measures sensory and motor conduction across the site of suspected compression. In CTS: prolonged distal motor latency (>4.2 ms), reduced sensory conduction velocity across the wrist (<40 m/s), or absent sensory response. MBS Item 11006/11012 (specialist request).

Available

Electromyography (EMG)

Needle EMG of muscles innervated by the suspected nerve (e.g., abductor pollicis brevis for CTS). Detects denervation changes (fibrillation, positive sharp waves) indicating axonal loss. Most useful when NCS is equivocal or to exclude proximal pathology (radiculopathy, plexopathy).

Laboratory Investigations (Screening for Systemic Causes)

Available

Fasting glucose / HbA1c

Screen for diabetes mellitus — present in up to 20% of CTS patients. Available at any Australian pathology laboratory (Medicare bulk-billed).

Available

Thyroid function tests (TSH, fT4)

Screen for hypothyroidism — associated with CTS and other entrapment neuropathies. Medicare bulk-billed.

Available

Inflammatory markers (CRP, ESR)

If inflammatory arthropathy suspected (rheumatoid arthritis, crystal arthropathy) as a cause of synovial hypertrophy within the carpal tunnel.

Available

FBC, renal function, liver function

Baseline assessment; renal impairment may affect gabapentinoid dosing. Screen for other causes of neuropathy (B12, folate if indicated).

Imaging

Available

Ultrasound of the wrist (carpal tunnel)

High-resolution ultrasound can demonstrate median nerve swelling (cross-sectional area >10–12 mm² at the carpal tunnel inlet is suggestive of CTS), nerve flattening, and space-occupying lesions (ganglion cysts, tenosynovitis). Increasingly used as a complementary or alternative diagnostic tool to NCS. Available in most radiology practices (MBS Item 55800 series).

Specialist

MRI of the wrist / elbow / spine

Reserved for cases with suspected space-occupying lesion, atypical presentations, or to exclude cervical radiculopathy as an alternative/comorbid diagnosis. Not routinely required for typical entrapment neuropathies.

Specialist

X-ray of the wrist / cervical spine

Plain radiographs are of limited value in entrapment neuropathies but may be indicated to exclude bony pathology (osteoarthritis, fractures, cervical spondylosis) in the differential diagnosis.

Risk Stratification & Severity Scoring

For carpal tunnel syndrome, clinical severity can be graded to guide management urgency and predict response to conservative versus surgical treatment. The Bland classification (modified) is widely used in Australian practice:

Mild

Intermittent Symptoms

Paraesthesiae occur only at night or with provocative activities. No motor deficit. No constant numbness. NCS: mild prolongation of sensory latency only, or borderline normal.

Setting: GP — splinting ± ergonomic modification. Reassess in 6–8 weeks.

Moderate

Frequent or Persistent Symptoms

Daily paraesthesiae, some daytime symptoms, may have mild weakness of thumb abduction but no wasting. NCS: clear sensory and/or motor latency prolongation.

Setting: GP — splinting + corticosteroid injection. Refer if no improvement in 8–12 weeks.

Severe

Constant Numbness ± Motor Deficit

Constant numbness in median distribution, thenar wasting, significant weakness of APB, functional impairment (dropping objects, difficulty with fine motor tasks). NCS: severe prolongation with reduced amplitudes, EMG may show denervation in APB.

Setting: Urgent specialist referral for surgical decompression. Pre-operative NCS recommended. Conservative management unlikely to reverse axonal loss.

🚨

Red flags requiring urgent referral: Acute-onset carpal tunnel symptoms (consider acute compartment syndrome, trauma), progressive motor deficit with thenar wasting, bilateral severe CTS in a young patient (consider hereditary neuropathy with liability to pressure palsies — HNPP), or symptoms suggesting a more proximal lesion (cervical myelopathy — look for upper motor neuron signs).

Empirical Therapy

Stepwise Approach to Carpal Tunnel Syndrome

1

Activity Modification & Splinting

Night-time wrist splint in neutral for 6–12 weeks. Avoid aggravating activities. Nerve gliding exercises. Treat underlying causes (optimise diabetes, thyroid, weight).

2

Corticosteroid Injection

If Step 1 insufficient after 4–6 weeks. Methylprednisolone 40 mg or triamcinolone 10–20 mg into carpal tunnel. Ultrasound guidance preferred. May repeat once after 8–12 weeks if initial good response.

3

Specialist Referral + NCS

If Steps 1–2 insufficient after 3 months total. NCS to confirm and grade severity. Assessment for surgical decompression. Consider neuropathic pain agents (gabapentin, pregabalin) for symptom relief while awaiting surgery.

4

Surgical Decompression

Open or endoscopic carpal tunnel release. Endoscopic may allow earlier return to work (1–2 weeks vs 3–4 weeks). Both have comparable long-term outcomes. Referral to hand surgeon or orthopaedic surgeon.

Pharmacological Options for Neuropathic Pain Component

While entrapment neuropathies are primarily mechanical problems, neuropathic pain agents may provide symptomatic relief while definitive treatment is arranged:

💊

Paracetamol + NSAIDs

Panadol® + Voltaren® / Nurofen® · Analgesic/anti-inflammatory

Adult dose Paracetamol 1 g QDS PRN ± ibuprofen 200–400 mg TDS or naproxen 250–500 mg BD with food

Duration Short courses (1–2 weeks) while initiating splinting/injection

Renal adjustment NSAIDs: avoid if eGFR <30; use with caution if eGFR 30–60

PBS status ✔ PBS General Benefit (OTC also available)

💊

Amitriptyline

Endep® · Generic available · Tricyclic antidepressant (neuropathic pain)

Adult dose 10 mg nocte, titrate to 25–50 mg nocte; max 75 mg nocte for pain

Renal adjustment No specific adjustment; use with caution

Hepatic adjustment Reduce dose in hepatic impairment; avoid in severe liver disease

Key side effects Dry mouth, drowsiness, constipation, urinary retention, weight gain, cardiac arrhythmia risk in overdose

PBS status ✔ PBS General Benefit

💡

Key principle: Neuropathic pain agents are adjunctive — they do not treat the underlying compression. They are most useful for symptom control while awaiting corticosteroid injection effect or surgical decompression. Do not delay definitive treatment in moderate-to-severe CTS.

Directed / Definitive Therapy

Carpal Tunnel Release Surgery

Surgical decompression (carpal tunnel release) is indicated for:

Severe CTS with constant numbness or thenar wasting.
Moderate CTS failing ≥3 months of conservative management (splinting + at least one corticosteroid injection).
Electrodiagnostically confirmed CTS with significant conduction impairment.
CTS caused by a space-occupying lesion (ganglion cyst, lipoma, tenosynovitis) amenable to excision.

Technique	Open Release	Endoscopic Release
Incision	3–4 cm palmar incision	1–2 small portal incisions
Average return to work	3–4 weeks	1–2 weeks
Long-term outcomes	Excellent (85–95% symptom relief)	Comparable
Risks	Palmar scar tenderness, pillar pain, nerve injury (rare)	Incomplete release, nerve/vessel injury (slightly higher risk with inexperienced operator)
Anaesthesia	Local ± sedation (day procedure)	Local ± sedation (day procedure)
Cost (private)	~$1,500–3,000 (surgeon + anaesthetic)	Similar or slightly higher

Post-Operative Rehabilitation

Hand elevation and gentle finger movements from day 1.
Wound care — keep dry for 5–7 days; sutures removed at 10–14 days.
Light desk work: 1–2 weeks (endoscopic) or 2–3 weeks (open).
Heavy manual work: 4–6 weeks (open) or 3–4 weeks (endoscopic).
Hand therapy referral if stiffness, weakness, or complex regional pain syndrome (CRPS) develops.

Cubital Tunnel — Surgical Options

For cubital tunnel syndrome requiring surgery:

In situ decompression — release of the cubital tunnel retinaculum (Osborne's ligament). Simplest technique; suitable for mild-to-moderate cases without nerve subluxation.
Anterior transposition — the ulnar nerve is moved anterior to the medial epicondyle (subcutaneous, intramuscular, or submuscular). Indicated when nerve subluxates or in revision surgery.
Medial epicondylectomy — removes the bony prominence compressing the nerve. Less commonly performed in modern practice.

Monitoring

Conservative Management Monitoring

Baseline

Assess symptom severity, perform provocative tests, examine for motor deficit/thenar wasting. Document functional impact. Screen for systemic risk factors (HbA1c, TFTs). Initiate splinting.

6–8 weeks

Reassess symptoms. If improved, continue splinting and wean over 2–4 weeks. If persistent, proceed to corticosteroid injection. If worsening, consider early NCS and referral.

12–16 weeks

Assess response to injection. If satisfactory and sustained, continue conservative management with PRN splinting. If relapse after injection response, consider repeat injection once or proceed to referral. If no response to injection, refer to specialist for NCS and surgical assessment.

6 months

If symptoms persist despite conservative measures, specialist surgical opinion should be obtained. NCS to guide surgical decision-making if not already performed.

Post-Surgical Monitoring

2 weeks: Wound check, suture removal, assess for early complications (infection, haematoma, nerve injury).
6 weeks: Assess symptom resolution, grip strength, wound healing. Most patients report significant improvement by this stage.
3 months: Formal review — assess for residual symptoms, pillar pain, scar tenderness. If no improvement, consider NCS and evaluate for incomplete release, incorrect diagnosis, or superimposed neuropathy.
Long-term: Recurrence rate after carpal tunnel release is 3–10%. Patients should be counselled that symptoms may recur, particularly if systemic risk factors are not addressed.

Special Populations

🤰 Pregnancy

CTS occurs in 20–45% of pregnancies, typically in the third trimester, due to fluid retention and hormonal effects on connective tissue.

Most cases (70–90%) resolve spontaneously within 3 months postpartum.

First-line: Night-time wrist splinting — safe and effective. Avoid corticosteroid injection unless severely symptomatic and failing splinting.

Medications: Gabapentin and pregabalin — avoid in pregnancy (Category B3/C). Paracetamol is safe for pain relief.

Surgery: Deferred until postpartum unless severe progressive motor deficit develops (rare).

Persistent CTS postpartum (beyond 6–12 months) should be investigated with NCS and managed as per non-pregnant guidelines.

👶 Paediatrics

Entrapment neuropathies are rare in children. When they occur, consider hereditary neuropathy with liability to pressure palsies (HNPP), mucopolysaccharidoses, or congenital anatomical anomalies.

Paediatric CTS typically presents atypically — pain and hand weakness rather than classic paraesthesiae.

NCS interpretation requires age-adjusted normative data; paediatric neurologist involvement recommended.

Medications: Gabapentin — can be used ≥12 years; dose titrated by paediatric neurologist.

In adolescents, consider repetitive device use (smartphones, gaming) as a contributing factor; ergonomic counselling is important.

👴 Elderly

Prevalence of CTS increases with age. Multiple concurrent neuropathies (e.g., diabetic polyneuropathy + CTS) are common and may confound diagnosis.

Elderly patients may present with atypical symptoms — more pain, less classic paraesthesiae; or may attribute symptoms to "arthritis."

Conservative management should be trialled first, but response rates may be lower than in younger patients.

Surgery: Outcomes are still generally favourable, though recovery may be slower. Age alone is not a contraindication to carpal tunnel release.

Medications: Amitriptyline — start at 5–10 mg nocte in elderly; risk of falls, confusion, urinary retention. Gabapentin/pregabalin — use lower doses; increased sensitivity to dizziness and sedation.

Polypharmacy review is essential — anticoagulants may affect suitability for corticosteroid injection or surgery.

🫘 Renal Impairment

Patients on haemodialysis have an exceptionally high prevalence of CTS (up to 10–30%) due to amyloid deposition, arteriovenous fistula-related changes, and fluid shifts during dialysis.

CTS in dialysis patients may occur in the fistula limb specifically — careful assessment is needed to distinguish from steal syndrome or dialysis-related ischaemia.

Medications: Gabapentin — dose reduction mandatory (see renal adjustment above). Pregabalin — dose reduction mandatory. NSAIDs — avoid if eGFR <30. Corticosteroid injection — no renal adjustment needed.

Surgical outcomes in dialysis patients are generally good but wound healing may be impaired.

🫁 Hepatic Impairment

Patients with chronic liver disease may have associated peripheral neuropathy, complicating the diagnosis of entrapment neuropathy.

Medications: Amitriptyline — reduce dose or avoid in severe hepatic impairment (impaired metabolism). Gabapentin — hepatic metabolism is minimal; no dose adjustment required. Pregabalin — hepatic metabolism minimal; no adjustment required.

Paracetamol — use at standard doses (≤4 g/day); caution with alcohol excess.

🛡️ Immunocompromised

Patients with inflammatory arthropathies (RA, psoriatic arthritis) on immunosuppressants may have synovitis-related CTS — corticosteroid injection is effective but consider infectious aetiology if atypical presentation.

HIV-associated neuropathy may co-exist with entrapment neuropathies; NCS helpful to distinguish.

Corticosteroid injection: Use with caution in patients on high-dose immunosuppression — ensure no local or systemic infection. No absolute contraindication.

Optimisation of the underlying inflammatory condition (e.g., DMARD therapy for RA) may reduce tenosynovitis and improve CTS symptoms.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander peoples experience a disproportionate burden of conditions that predispose to entrapment neuropathies, yet face significant barriers to timely diagnosis and treatment. Culturally safe, person-centred care is essential.

Diabetes prevalence

Type 2 diabetes affects approximately 8% of Aboriginal and Torres Strait Islander adults (vs 4.8% non-Indigenous), with many more undiagnosed. Diabetes is the strongest systemic risk factor for entrapment neuropathy and must be actively screened and managed as part of comprehensive care. Peripheral neuropathy from diabetes may co-exist with and mask entrapment neuropathies.

Obesity

Obesity rates are higher in Aboriginal and Torres Strait Islander populations (37% vs 31% in non-Indigenous). Obesity is a significant modifiable risk factor for both CTS and meralgia paraesthetica. Culturally appropriate weight management programmes should be integrated into chronic disease management plans (MBS Item 721).

Remote access barriers

Many Aboriginal and Torres Strait Islander people live in remote or very remote areas with limited access to neurophysiology services (NCS/EMG), hand surgeons, and specialist clinics. Telehealth consultations (MBS Items 99–113) can facilitate specialist assessment. Point-of-care ultrasound for carpal tunnel assessment may be available in some Aboriginal Community Controlled Health Services (ACCHS).

Occupational and manual labour

Higher rates of manual work and physical occupations in some communities may contribute to entrapment neuropathy risk. Workplace ergonomic assessment and modification should be supported through Safe Work Australia frameworks.

Cultural considerations

Pain expression and health-seeking behaviour may differ; clinicians should use culturally safe communication, involve Aboriginal and Torres Strait Islander health workers in assessment and education, and respect the patient's priorities and timeline for treatment. Avoid assumptions about compliance — barriers are structural, not personal. Where possible, provide care through ACCHS or with Aboriginal liaison officer support.

Healthcare access and Closing the Gap

The National Agreement on Closing the Gap (2020) prioritises access to culturally safe healthcare. GPs can utilise Indigenous health checks (MBS Item 715) to screen for diabetes, obesity, and peripheral/entrapment neuropathy symptoms. Chronic disease management plans (MBS Item 723) and team care arrangements (MBS Item 732) enable multidisciplinary care involving physiotherapy and hand therapy.

ℹ️

Key action for GPs: During MBS Item 715 health checks in Aboriginal and Torres Strait Islander patients, specifically ask about hand numbness, nocturnal symptoms, and grip weakness — these are often unreported unless directly asked. Early identification and conservative management can prevent surgical referral and improve outcomes in communities where access to surgery may be significantly delayed.

📚 References

1. Padua L, Coraci D, Erra C, et al. Carpal tunnel syndrome: clinical features, diagnosis, and management. Lancet Neurol. 2016;15(12):1273–1284.
2. Bland JD. Carpal tunnel syndrome. BMJ. 2007;335(7615):343–346.
3. Huisstede BM, Hoogvliet P, Randsdorp MS, et al. Carpal tunnel syndrome. Part I: effectiveness of nonsurgical treatments — a systematic review. Arch Phys Med Rehabil. 2010;91(7):981–1004.
4. Shi Q, MacDermid JC. Is surgical intervention more effective than non-surgical treatment for carpal tunnel syndrome? A systematic review. J Orthop Surg Res. 2011;6:17.
5. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework. Canberra: AIHW; 2023.
6. Royal Australian College of General Practitioners (RACGP). Management of type 2 diabetes: A handbook for general practice. Melbourne: RACGP; 2020.
7. Descatha A, Leclerc A, Chastang JF, Roquelaure Y; Study Group on Repetitive Work. Incidence of ulnar nerve entrapment at the elbow in repetitive work. Scand J Work Environ Health. 2004;30(3):234–240.
8. Safe Work Australia. Work-related musculoskeletal disorders in Australia. Canberra: Safe Work Australia; 2019.
9. Elnady B, Ekber M, Getha K, et al. Ultrasound for diagnosis of carpal tunnel syndrome: a systematic review and meta-analysis. J Ultrasound Med. 2023;42(5):1021–1034.
10. Necking LE, Dahlin LB, Fridén J. Clinical assessment of nerve compression: provocative tests and their diagnostic value. J Hand Surg Eur. 2020;45(8):803–810.
11. National Health and Medical Research Council (NHMRC). National Statement on Ethical Conduct in Human Research. Canberra: NHMRC; 2018 (updated 2023).
12. Burke FD, Wilgis EFS, Dubin NH, et al. Relationship between the duration and type of symptoms and severity of carpal tunnel syndrome. J Hand Surg Eur. 2009;34(5):637–640.
13. Cheung C, Podemos S, Shah M. Meralgia paraesthetica: an update on diagnosis and management. Aust J Gen Pract. 2021;50(10):718–723.
14. RHDAustralia (Remote Health Division, NT Department of Health). Minimising the risk of rheumatic heart disease in Aboriginal and Torres Strait Islander peoples. Darwin: RHDAustralia; 2022.
15. Fajardo M, Kim SH, Szabo RM. Incidence of carpal tunnel release: trends and implications within the United States ambulatory care setting. J Hand Surg Am. 2012;37(8):1599–1605.